Cue Biopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Cue Biopharma, Inc. (CUE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.19% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-14
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 3.98%, a 10.76% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.46%, a 4.21% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.28%, a 7.27% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-03-31 was 3.99%, a 55.86% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.46%, a 0.68% increase from fiscal 2024.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.43%, a 5.23% increase from fiscal 2023.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.21%, a 44.18% increase from fiscal 2022.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 2.92%, a 104.20% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 4.19% 10-Q · filed 2026-08-14 | |||||
| 2026-03-31 | 3.98% 10-Q · filed 2026-05-14 | |||||
| 2025-12-31 | 4.46% 10-K · filed 2026-03-16 | |||||
| 2025-09-30 | 4.46% 10-Q · filed 2025-11-12 | |||||
| 2025-06-30 | 4.46% 10-Q · filed 2026-08-14 | |||||
| 2025-03-31 | 4.46% 10-Q · filed 2026-05-14 | |||||
| 2024-12-31 | 4.43% 10-K · filed 2026-03-16 | |||||
| 2024-09-30 | 4.43% 10-Q · filed 2025-11-12 | |||||
| 2024-06-30 | 4.43% 10-Q · filed 2025-08-12 | |||||
| 2024-03-31 | 4.28% 10-Q · filed 2025-05-12 | |||||
| 2023-12-31 | 4.21% 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | 4.16% 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | 3.99% 10-Q · filed 2024-08-14 | |||||
| 2023-03-31 | 3.99% 10-Q · filed 2024-05-09 | |||||
| 2022-12-31 | 2.92% 10-K · filed 2024-03-28 | |||||
| 2022-09-30 | 2.92% 10-Q · filed 2023-11-03 | |||||
| 2022-06-30 | 2.56% 10-Q · filed 2023-08-08 | |||||
| 2022-03-31 | 2.56% 10-Q · filed 2023-05-09 | |||||
| 2021-12-31 | 1.43% 10-K · filed 2023-03-21 | |||||
| 2021-09-30 | 1.31% 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 1.31% 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | 1.18% 10-Q · filed 2022-05-10 | |||||
| 2020-12-31 | 1.56% 10-K · filed 2022-03-16 | 2.58% 10-K · filed 2021-03-09 | ||||
| 2020-09-30 | 1.56% 10-Q · filed 2021-11-09 | 1.78% 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | 1.56% 10-Q · filed 2021-08-09 | |||||
| 2020-03-31 | 1.56% 10-Q · filed 2021-05-10 | |||||
| 2019-12-31 | 2.95% 10-K · filed 2021-03-09 | 2.58% 10-K · filed 2020-03-12 | ||||
| 2019-09-30 | 2.59% 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | 2.59% 10-Q · filed 2020-08-07 | |||||
| 2019-03-31 | 2.59% 10-Q · filed 2019-05-08 | |||||
| 2018-12-31 | 2.95% 10-K · filed 2020-03-12 | |||||
| 2018-09-30 | 2.92% 10-Q · filed 2018-11-13 | |||||
| 2018-06-30 | 2.92% 10-Q · filed 2018-08-13 | |||||
| 2018-03-31 | 2.62% 10-Q · filed 2018-05-14 | |||||
| 2017-12-31 | 2.22% 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |